Immunoprecise Antibodies (IPA) Financials
$1.77
$-0.30
(-14.49%)
As on 02-Oct-2025 09:30EDT
Market cap
$96 Mln
Revenue (TTM)
$25 Mln
P/E Ratio
--
P/B Ratio
5.6
Div. Yield
0 %
Cashflow (CA$ Mln) |
Apr-25 | Apr-24 | Apr-23 | Apr-22 | Apr-21 | Apr-20 | Apr-19 | Apr-18 | Apr-17 | Apr-16 | Apr-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-6.41
|
-4.25
|
-19.83
|
-9.92
|
-0.60
|
-1.39
|
|
|
|
|
|
|
Cash Flow from Investing Activities
|
-0.80
|
-1.56
|
-1.97
|
-5.21
|
-2.46
|
-1.58
|
|
|
|
|
|
|
Cash from Financing Activities
|
14.89
|
1.02
|
-0.62
|
2.88
|
43.38
|
0.17
|
|
|
|
|
|
|
Net Cash Inflow / Outflow
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
Financials Ratios |
Apr-25 | Apr-24 | Apr-23 | Apr-22 | Apr-21 | Apr-20 | Apr-19 | Apr-18 | Apr-17 | Apr-16 | Apr-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Adjusted EPS (CA$)
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
Cash EPS (CA$)
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
Adjusted Book Value (CA$)
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
Dividend per Share (CA$)
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
Cash Flow per Share (CA$)
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
Free Cash Flow per Share (CA$)
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
Profitability Ratios |
Apr-25 | Apr-24 | Apr-23 | Apr-22 | Apr-21 | Apr-20 | Apr-19 | Apr-18 | Apr-17 | Apr-16 | Apr-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
ROCE (%)
|
-71.45
|
-48.24
|
-37.17
|
-24.18
|
-18.36
|
-24.37
|
|
|
|
|
|
|
ROE (%)
|
-105.08
|
-59.26
|
-39.91
|
-25.28
|
-20.39
|
-29.84
|
|
|
|
|
|
|
ROA (%)
|
-57.90
|
-39.44
|
-31.01
|
-20.83
|
-15.58
|
-17.79
|
|
|
|
|
|
|
EBIT Margin (%)
|
-138.56
|
-116.99
|
-134.15
|
-81.40
|
-28.65
|
-27.43
|
|
|
|
|
|
|
Net Margin (%)
|
-123.30
|
-110.85
|
-128.53
|
-86.29
|
-40.98
|
-35.19
|
|
|
|
|
|
|
Cash Profit Margin (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
Growth Ratios |
Apr-25 | Apr-24 | Apr-23 | Apr-22 | Apr-21 | Apr-20 | Apr-19 | Apr-18 | Apr-17 | Apr-16 | Apr-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.00
|
0.19
|
0.07
|
0.08
|
0.27
|
0.29
|
|
|
|
|
|
|
EBIT Growth (%)
|
-18.44
|
-3.47
|
-75.87
|
-207.15
|
-33.09
|
38.74
|
|
|
|
|
|
|
Net Profit Growth (%)
|
-11.25
|
-2.32
|
-58.96
|
-127.64
|
-48.37
|
35.05
|
|
|
|
|
|
|
EPS Growth (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
Book Value Growth (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
Solvency Ratios |
Apr-25 | Apr-24 | Apr-23 | Apr-22 | Apr-21 | Apr-20 | Apr-19 | Apr-18 | Apr-17 | Apr-16 | Apr-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debt to Equity
|
0.57
|
0.40
|
0.13
|
0.03
|
0.06
|
0.30
|
|
|
|
|
|
|
Short term debt to equity ratio
|
0.08
|
0.05
|
0.02
|
0.03
|
0.02
|
0.19
|
|
|
|
|
|
|
Current Ratio
|
2.08
|
1.41
|
2.84
|
4.05
|
8.05
|
0.97
|
|
|
|
|
|
|
Quick Ratio
|
1.85
|
1.15
|
2.49
|
3.87
|
7.85
|
0.87
|
|
|
|
|
|
|
Interest Coverage
|
-115.95
|
-1,509.68
|
-924.07
|
-185.45
|
-5.95
|
-2.69
|
|
|
|
|
|
Operating Efficiency Ratios |
Apr-25 | Apr-24 | Apr-23 | Apr-22 | Apr-21 | Apr-20 | Apr-19 | Apr-18 | Apr-17 | Apr-16 | Apr-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debtors to sales (%)
|
19.60
|
16.59
|
21.36
|
17.60
|
23.00
|
26.03
|
|
|
|
|
|
|
Asset Turnover
|
0.47
|
0.36
|
0.24
|
0.24
|
0.38
|
0.51
|
|
|
|
|
|
|
Receivable days
|
66.09
|
63.18
|
69.14
|
71.00
|
79.31
|
72.90
|
|
|
|
|
|
|
Inventory Days
|
70.47
|
61.52
|
73.74
|
61.43
|
57.95
|
89.11
|
|
|
|
|
|
|
Payable days
|
155.71
|
96.05
|
128.43
|
114.66
|
77.33
|
89.37
|
|
|
|
|
|
|
Cash Conversion Cycle
|
-19.15
|
28.65
|
14.45
|
17.76
|
59.94
|
72.65
|
|
|
|
|
|
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
